EUVIMEDEUVIMED entdecken
KorrekturOpen Access

Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”

Cancer · 15.08.2026 · 132 (16)

DOI: 10.1002/cncr.70508 ↗

Kurz gefasst

Korrektur in der Zeitschrift Cancer, online erschienen am 13.08.2026. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”. Cancer, 132(16). https://doi.org/10.1002/cncr.70508

Vancouver

Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”. Cancer. 2026;132(16). doi:10.1002/cncr.70508

BibTeX
@article{euvimed2026,
  title = {Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {16},
  doi = {10.1002/cncr.70508}
}
Kostenlos starten →